Anagenics Ltd has released a press release.
Cellmid Sets Another Sales Record in Q4 FY2019
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Anagenics
- Cellmids Evolis Registered in European Union (EU)
- Minimum Holding Share Buy-Back
- Appendix 4D, Half Year Accounts and Strategy Update
- Significant New Findings Published on Midkine
- Cellmid: Appendix 4C and Notes to Appendix 4C
Later from Anagenics
- Response to Appendix 4C Query
- CDY Signs Distribution Agreement for EVOLIS in South Korea
- Patent for Improved Midkine Antibody Allowed in Europe
- FY2019 Financial Results
- New Evolis Distribution & Supply Agreements - China & Europe
Follow Anagenics into a list and get an email when it puts out news.
Follow Anagenics